"Unblinding" occurs in a blinded experiment when information is revealed to someone to whom it has been masked. In clinical studies, unblinding may occur unintentionally when a patient deduces their treatment group. Unblinding that occurs before the conclusion of an
experiment is a source of
bias. Some degree of premature unblinding is common in blinded experiments. When a blind is imperfect, its success is judged on a
spectrum with
no blind (or complete failure of blinding) on one end, perfect blinding on the other, and poor or good blinding between. Thus, the common view of studies as blinded or unblinded exemplifies a
false dichotomy. The success of blinding is assessed by asking study participants about information that has been masked from them (e.g., whether the participant received the drug or
placebo?). In a perfectly blinded experiment, the responses should be consistent with no knowledge of the masked information. However, if unblinding has occurred, the responses will indicate the degree of unblinding. Since unblinding
cannot be measured directly, but must be inferred from participants' responses, its measured value will depend on the
nature of the questions asked. As a result, it is not possible to objectively measure unblinding. Nonetheless, it is still possible to make informed judgments about the quality of a blinding. Poorly blinded studies rank above unblinded studies and below well-blinded studies in the
hierarchy of evidence.
Post-study unblinding Post-study unblinding is the release of masked data upon completion of a study. In
clinical studies, post-study unblinding informs subjects of their
treatment allocation. Removing a blind upon completion of a study is never mandatory, but is typically performed as a courtesy to study participants. Unblinding that occurs after the conclusion of a study is not a source of bias, because data collection and analysis are both complete at this time.
Premature unblinding Premature unblinding is any unblinding that occurs before the conclusion of a study. In contrast with post-study unblinding, premature unblinding is a source of bias. A
code-break procedure dictates when a subject should be unblinded prematurely. A code-break procedure should allow unblinding only in cases of emergency. Unblinding that occurs in compliance with the code-break procedure is strictly documented and reported. Premature unblinding may also occur when a participant infers, from the experimental conditions, information that has been masked from him. A common cause for unblinding is the presence of side effects (or effects) in the treatment group. In pharmacological trials, premature unblinding can be reduced with the use of an
active placebo, which conceals treatment allocation by ensuring the presence of side effects in both groups. However, side effects are not the only cause of unblinding; any perceptible difference between the treatment and control groups can contribute to premature unblinding. A problem arises in assessing blinding because asking subjects to guess masked information may prompt them to infer it. Researchers speculate that this may contribute to premature unblinding. Furthermore, it has been reported that some subjects of clinical trials attempt to determine if they have received an active treatment by gathering information on social media and message boards. While researchers counsel patients not to use social media to discuss clinical trials, their accounts are not monitored. This behavior is believed to be a source of unblinding. CONSORT standards and
good clinical practice guidelines recommend the reporting of all premature unblinding. In practice, unintentional unblinding is rarely reported. Some researchers have called for the mandatory assessment of blinding efficacy in clinical trials. == Applications ==